Belgium· BE-AMP-SAM213665-00
ViraferonPeg 50 µg
A peginterferon alfa-2b product containing peginterferon alfa-2b, registered in Belgium by Merck Sharp & Dohme. The same ATC class is registered in 5 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Peginterferon alfa-2b is registered in 5 of 19 countries.
Countries holding a registration under ATC L03AB10 (peginterferon alfa-2b), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 2 of them publish a price we can compare per daily dose
Peginterferon alfa-2b · ATC L03AB10
5 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Netherlands
- United Kingdom
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Peginterferon Alfa-2b
- Manufacturer
- Merck Sharp & Dohme
- Country
- Belgium (BE)
- ATC code
- L03AB10
- ATC class
- Peginterferon alfa-2b
- Defined daily dose
- 15 mcg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
199 interactions on record for peginterferon alfa-2b.
Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Peginterferon alfa-2b · interactions on record
199 records
- 36 severe
- 161 moderate
- 2 minor
Most severe, free to view
- EltrombopagB02BX05severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- ZidovudineJ05AF01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Peginterferon alfa-2b in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomPegIntron 50microgram powder and solvent for solution for injection vialsSchering-Plough Ltd
- SpainPEGINTRON 50 microgramos POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEMerck Sharp & Dohme B.V.
- FinlandPegintronMerck Sharp & Dohme B.V.
- NetherlandsPegIntron 100 microgram poeder en oplosmiddel voor oplossing voor injectieMerck Sharp & Dohme B.V.
- DenmarkPegIntronMerck Sharp & Dohme B.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e0c3f637-6a55-4a22-bd44-5fda722bf758 GET /v1/drugs/e0c3f637-6a55-4a22-bd44-5fda722bf758?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solvent for solution for injection",
"source": "afmps",
"status": "REVOKED",
"name_en": "ViraferonPeg 50 µg",
"name_fr": "ViraferonPeg 50 µg",
"name_nl": "ViraferonPeg 50 µg",
"amp_code": "SAM213665-00",
"strengths": [
"50.0000",
"50.0000",
"50.0000"
],
"pack_count": 5,
"substances": [
"Peginterferon Alfa-2b"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Peginterferon Alfa-2b",
"authorisation_numbers": [
"EU/1/00/132/001",
"EU/1/00/132/003",
"EU/1/00/132/002",
"EU/1/00/132/026",
"EU/1/00/132/004"
]
}See everything about peginterferon alfa-2b.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.